NF2 and Miyoshi myopathy: NF2 deficiency, reported in 40% of MM cases [18], leads to inactivation of the tumor-suppressive Hippo pathway [19] and activation of multiple oncogenic pathways, which promote cell proliferation, migration, and survival [20].